Does It Matter How You Lower LDL or How You Raise HDL?

Size: px
Start display at page:

Download "Does It Matter How You Lower LDL or How You Raise HDL?"

Transcription

1 1

2 Does It Matter How You Lower LDL or How You Raise HDL? Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease UCSF 25 th Annual Advances in Heart disease 12 December 2008 Disclosures: Research and educational grants, consulting and promotional speaking for Abbott, AstraZeneca, Merck, Merck Schering-Plough, Pfizer, GSK 2

3 Does It Matter How Whether You Lower LDL or How You Raise HDL? Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease UCSF 25 th Annual Advances in Heart disease 12 December 2008 Disclosures: Research and educational grants, consulting and promotional speaking for Abbott, AstraZeneca, Merck, Merck Schering-Plough, Pfizer, GSK 3

4 Prevalence of Abnormal Levels of LDL-C and HDL-C in 8,500 CHD Patients* LDL-C > 130 mg/dl - 58 % HDL-C < 40 mg/dl - 67 % LDL-C < 130mg/dL & - 29 % HDL-C < 40 mg/dl * Distribution of Lipids in 8,500 Men with Coronary Artery Disease. Rubins HB et al., Am J Cardiol 75: (1995) 4

5 5

6 6

7 Hazard Ratios of Future CHD Events in 15,652 Healthy Women (Highest vs. Lowest Quintiles of Each Variable) Ridker, P. M et al. JAMA 2005;294: Copyright restrictions may apply. 7

8 Relating Lipid Changes to CHD Risk Reductions Reduction in Total Cholesterol R 2 =0.55 Reduction in LDL Cholesterol R 2 =0.53 Reduction in Triglyceride R 2 =0.45 Increase in HDL Cholesterol R 2 =0.65 Reduction in Non-HDL C R 2 =0.65 Reduction in TC/HDL C R 2 =0.86 Meta-analysis by A. Alsheik-Ali, HM Abourjally, E Stanek, M McGovern, JT Kuvin, and RH Karas, Tufts-New England Medical Ctr, Boston, Abstract presented at AHA 2004, based on 3,869 CHD events occurring in 44,170 subjects participating in randomized placebo controlled lipid intervention trials-hhs, FATS, HATS, 4S, WOSCOPS, LIPID, AFCAPS/TEXCAPS, VA-HIT, BIP, DAIS, HPS, PROSPER, ALL-HAT-LLT, ASCOT-LLA 8

9 9

10 10

11 11

12 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl

13 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl =

14 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl = =

15 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl = =

16 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = mg/dl = =

17 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

18 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = ! 161 mg/dl = =

19 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

20 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

21 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

22 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

23 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

24 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =

25 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C % LDL-C 161 mg/dl = = /99=76 % 161 mg/dl = = /189=63% 25

26 26

27 Absolute values of LDL-C and HDL-C are less important than their relationship to each other as assessed by ratios Total cholesterol/hdl-c LDL-C/HDL-C Apolipoprotein B / apolipoprotein AI 27

28 Does It Matter How You Lower LDL or How You Raise HDL? LDL getting to goal is important, but how you get there (i.e. which medicines you use) is not. STATIN FIRST (more evidence). HDL raising HDL-C can be dangerous (consider estrogen and the cholesterol ester transfer protein inhibitor, torcetrapib). For every new drug that raises HDL-C a mortality and morbidity outcomes trial will be required to establish efficacy and safety. 28

29 Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?* Meta-analysis of 5 diet, 3 bile acid sequestrant, 1 partial ileal bypass surgery and 10 statin trials. 81,859 subjects 3 or more years of follow-up (most 5 years) Uniform primary outcome: CHD death or nonfatal myocardial infarction * Robinson J et al., J Am Coll Cardiol 46: (2005) 29

30 Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction? * Result: no difference in the relationship of CHD event reduction and LDL-C reduction irrespective of how LDL-C was lowered. Conclusion: statin benefit is almost entirely due to lowering of LDL-C. The putative clinical benefit of the Pleiotropic effects of statins requires further study. * Robinson J et al., J Am Coll Cardiol 46: (2005) 30

31 31

32 Raising HDL-C Niacin - up to 30% Statins, fibrates % Exercise - dose related (HDL-C varied from 47 to 56 mg/dl in healthy men running 0 to 31 miles weekly*) Ethanol up to 20 %; dose dependent Saturated fat restriction lowers HDL-C * Miles run per week and HDL cholesterol levels in healthy, middle-aged men. Arch Int Med 155: (1995) 32

33 33

34 Characteristics of People with Lowest Risk of Heart Attack (Framingham Heart Study) LDL-C= mg/dl BP < 120/80 (no HTN rx)* HDL-C>60 mg/dl* non-diabetic* non-smoker * Not too common in the overweight or obese Wilson et. al. Circ. 97: (1998) 34

35 The Singing Lipidologist 35

36 Scientific Sessions 05 Dallas, Texas Mammas don t let your babies grow up to be couch girls (orchow boys ) (Apologies and thanks to Waylon and Willie) 36

37 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 37

38 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 38

39 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 39

40 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 40

41 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 41

42 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 42

43 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 43

44 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 44

45 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 45

46 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 46

47 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 47

48 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 48

49 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 49

50 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 50

51 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys! Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 51

52 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys, Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 52

53 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 73 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 53

54 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 54

55 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 55

56 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 56

57 Mammas, don t let your babies grow up an have MI s. Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 57

58 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 58

59 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 59

60 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 60

61 61

62 62

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

Lipid Management: Beyond LDL

Lipid Management: Beyond LDL Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine

More information

Raising high-density lipoprotein cholesterol: where are we now?

Raising high-density lipoprotein cholesterol: where are we now? European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;

More information

STATINS FOR PAD Long - term prognosis

STATINS FOR PAD Long - term prognosis STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest

More information

When it comes to the FIELD study, what is...is

When it comes to the FIELD study, what is...is Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

The Target is LDL, HDL not so much

The Target is LDL, HDL not so much The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013

More information

Treating Lipids for Prevention of CAD in Women: Matching Therapy to Risk

Treating Lipids for Prevention of CAD in Women: Matching Therapy to Risk TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

Advances in Lipid Management

Advances in Lipid Management Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center

More information

CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE

CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring

More information

The Pharmacists Role in Lipid Management

The Pharmacists Role in Lipid Management The Pharmacists Role in Lipid Management Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Learning Objectives 1. ENHANCE your understanding

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

CHOLESTEROL CONTENT CREATED BY. Learn more at

CHOLESTEROL CONTENT CREATED BY. Learn more at CHOLESTEROL CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents what is cholesterol? 4 Whether this is your first visit or a follow-up, asking your doctor these

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Medical evidence suggests that

Medical evidence suggests that COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and

More information

Calculating RR, ARR, NNT

Calculating RR, ARR, NNT Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

Young high risk patients the role of statins Dr. Mohamed Jeilan

Young high risk patients the role of statins Dr. Mohamed Jeilan Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

COURAGE to Leave Diseased Arteries Alone

COURAGE to Leave Diseased Arteries Alone COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

The Cardiovascular Institute Mount Sinai School of Medicine, New York

The Cardiovascular Institute Mount Sinai School of Medicine, New York The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine

More information

Cholesterol Treatment Update

Cholesterol Treatment Update Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Controversies in Preventative Cardiology

Controversies in Preventative Cardiology Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence

More information

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of

More information

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD 2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:

More information

Qué factores de riesgo lipídicos debemos controlar? En qué medida?

Qué factores de riesgo lipídicos debemos controlar? En qué medida? Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk

More information

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,

More information

Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환

Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Presentation General LDL cholesterol HDL cholesterol Future Summary A top healthcare priority 사망 / 인구 10 만 Causes of Death Worldwide, 2008 140 120 2008 년 한국인 5 대사망원인

More information

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018 Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018

More information

Prevention of Heart Disease. Giridhar Vedala, MD Cardiovascular Medicine

Prevention of Heart Disease. Giridhar Vedala, MD Cardiovascular Medicine Prevention of Heart Disease Giridhar Vedala, MD Cardiovascular Medicine What is Heart Disease? Heart : The most hard-working muscle of our body pumps 4-5 liters of blood every minute during rest Supplies

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

Since the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT

Since the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large

More information

Statins in the elderly : Is there a rationale?

Statins in the elderly : Is there a rationale? Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,

More information

The Metabolic Syndrome

The Metabolic Syndrome The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver)

1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver) I. TEST YOUR KNOWLEDGE OF CHOLESTEROL Choose the correct answer. 1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver) 2. Only

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system LEARN Learn about HTHU Level 3 and the point system 01 IDENTIFY Identify the major risk factors for cardiovascular disease and how to improve our cardiovascular health 03 02 ACT Begin our Session 1 Goal

More information

ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC/EAS Guidelines for the Management of Dyslipidaemias ESC/EAS Guidelines for the Management of Dyslipidaemias Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC University Hospital Center Zagreb School of Medicine, University of Zagreb, Croatia Declaration

More information

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No

More information

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of: Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,

More information

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated

More information

Understanding Cholesterol and Triglycerides

Understanding Cholesterol and Triglycerides MINTO PREVENTION & REHABILITATION CENTRE CENTRE DE PREVENTION ET DE READAPTATION MINTO Understanding Cholesterol and Triglycerides About This Kit Along with cigarette smoking, high blood pressure, physical

More information

A N A C P S P E C I A L R E P O R T. Understanding and Managing Your. Triglycerides

A N A C P S P E C I A L R E P O R T. Understanding and Managing Your. Triglycerides A N A C P S P E C I A L R E P O R T Understanding and Managing Your Triglycerides What are Triglycerides? Triglycerides are one of several types of fat in your body, and the most common of them all. Along

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

OM s Health Corner Cholesterol & Heart Disease!!

OM s Health Corner Cholesterol & Heart Disease!! Cholesterol & Heart Disease!! We may associate cholesterol with fatty foods, but most of the waxy substance is made by our own bodies. The liver produces 75% of the cholesterol that circulates in our blood.

More information

Safety of Anacetrapib in Patients with or

Safety of Anacetrapib in Patients with or Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.

More information

WHAT ABOUT AIM-HIGH?

WHAT ABOUT AIM-HIGH? WHAT ABOUT AIM-HIGH? WHERE DID WE GO WRONG--OR DID WE? AIM-HIGH: ATHEROTHROMBOSIS INTERVENTIONS IN METABOLIC SYNDROME WITHLOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES. Funded by NHLBI,

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Normal cholesterol level for men over 50

Normal cholesterol level for men over 50 Normal cholesterol level for men over 50 Understand what your cholesterol levels mean: Total, LDL, for men and 50 mg per dl their respective numbers have to stay over or under a particular level,. 24-4-2017

More information

LAMIS (Livalo in AMI Study)

LAMIS (Livalo in AMI Study) JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia

More information

What do the guidelines say about combination therapy?

What do the guidelines say about combination therapy? What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,

More information

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Biomarkers are NOT useful Surrogates in Lipid Lowering Trials, but they are great Biomarkers!

Biomarkers are NOT useful Surrogates in Lipid Lowering Trials, but they are great Biomarkers! Biomarkers are NOT useful Surrogates in Lipid Lowering Trials, but they are great Biomarkers! Robert M Califf MD Vice Chancellor for Clinical Research Duke University CHD Mortality Rate Per 1000 Total

More information

STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP

STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois

More information

RECOGNITION OF THE METABOLIC SYNDROME

RECOGNITION OF THE METABOLIC SYNDROME THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary

More information

The Clinical Debates

The Clinical Debates The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University

More information

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information